Advertisement

PharmacoEconomics & Outcomes News

, Volume 821, Issue 1, pp 21–21 | Cite as

Omalizumab add-on therapy cost effective in severe asthma in Spain

Clinical study

Reference

  1. Entrenas Costa LM, et al. Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World Study. PharmacoEconomics-Open : 25 Jan 2019. Available from: URL: https://doi.org/10.1007/s41669-019-0117-4

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations